登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，8月13日，A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-08-19

  • A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

    Antonio E. Muruato, Camila R. Fontes-Garfias, Ping Ren, Mariano A. Garcia-Blanco, Vineet D. Menachery, Xuping Xie & Pei-Yong Shi

    Nature Communications volume 11, Article number: 4059 (2020)

    Abstract

    Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.

  • 原文来源：https://www.nature.com/articles/s41467-020-17892-0#auth-Antonio_E_-Muruato
6浏览量
原文链接
相关报告

  • 《8月13日_用于COVID-19诊断和疫苗评估的高通量中和抗体检测》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-08-18
    • Nature Communications期刊于8月13日发表了德克萨斯大学医学院的研究文章“A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation”。文章指出，病毒中和仍然是确定抗体功效的金标准。因此，对于COVID-19血清诊断、恢复期血浆疗法和疫苗开发，迫切需要一种用于检测SARS-CoV-2中和抗体的高通量分析方法。该文中，研究人员报告了一种基于荧光的SARS-CoV-2中和检测方法，可以检测COVID-19患者标本中的SARS-CoV-2中和抗体，其结果与噬斑减少中和试验这种血清学测试的黄金标准的结果相当。这种基于荧光的中和检测方法可特异性地检测COVID-19中和抗体，而不会与其它病毒、细菌或寄生虫感染的患者标本发生交叉反应。 原文链接：https://www.nature.com/articles/s41467-020-17892-0#auth-Antonio_E_-Muruato
    121浏览量
    原文链接

  • 《Nature，11月27日，RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-12-22
    • RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response Zezhong Liu, Wei Xu, Shuai Xia, Chenjian Gu, Xinling Wang, Qian Wang, Jie Zhou, Yanling Wu, Xia Cai, Di Qu, Tianlei Ying, Youhua Xie, Lu Lu, Zhenghong Yuan & Shibo Jiang Signal Transduction and Targeted Therapy volume 5, Article number: 282 (2020) Abstract The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed serious threats to global health and economy, thus calling for the development of safe and effective vaccines. The receptor-binding domain (RBD) in the spike protein of SARS-CoV-2 is responsible for its binding to angiotensin-converting enzyme 2 (ACE2) receptor. It contains multiple dominant neutralizing epitopes and serves as an important antigen for the development of COVID-19 vaccines. Here, we showed that immunization of mice with a candidate subunit vaccine consisting of SARS-CoV-2 RBD and Fc fragment of human IgG, as an immunopotentiator, elicited high titer of RBD-specific antibodies with robust neutralizing activity against both pseudotyped and live SARS-CoV-2 infections. The mouse antisera could also effectively neutralize infection by pseudotyped SARS-CoV-2 with several natural mutations in RBD and the IgG extracted from the mouse antisera could also show neutralization against pseudotyped SARS-CoV and SARS-related coronavirus (SARSr-CoV). Vaccination of human ACE2 transgenic mice with RBD-Fc could effectively protect mice from the SARS-CoV-2 challenge. These results suggest that SARS-CoV-2 RBD-Fc has good potential to be further developed as an effective and broad-spectrum vaccine to prevent infection of the current SARS-CoV-2 and its mutants, as well as future emerging SARSr-CoVs and re-emerging SARS-CoV.
    210浏览量
    原文链接